Macular Telangiectasia Type 2: A Comprehensive Review

Clin Ophthalmol. 2022 Oct 10:16:3297-3309. doi: 10.2147/OPTH.S373538. eCollection 2022.

Abstract

Macular telangiectasia Type 2 (MacTel) is a gradually progressive disease that affects the quality of life by impairing both distant and near vision. It had previously been considered a vascular condition, but recent evidence suggests a neurodegenerative etiology, with primary involvement of Muller cells. Retinal pigment epithelium (RPE) hyperplasia and subretinal neovascularization (SNV) are responsible for most of the vision loss in advanced cases. Neurotrophic factors in the non-proliferative phase and intravitreal anti-Vascular Endothelial growth factor (VEGF) in the proliferative phase have shown to retard the progression of the disease. This review will discuss the pathophysiology, clinical features, important diagnostic imaging studies and available treatment options for MacTel.

Keywords: CNTF; MacTel; ciliary neurotrophic factor; macular telangiectasia type 2.

Publication types

  • Review